Thryv Holdings, Inc. (THRY)
| Previous Close | 21.07 |
| Open | 20.92 |
| Bid | 21.00 x 100 |
| Ask | 26.99 x 200 |
| Day's Range | 20.95 - 21.41 |
| 52 Week Range | 15.99 - 26.42 |
| Volume | |
| Avg. Volume | 174,590 |
| Market Cap | 758.717M |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Thryv to Participate in Upcoming Investor Conferences
DALLAS, May 29, 2024--Thryv Holdings, Inc. (NASDAQ:THRY) ("Thryv" or the "Company"), the provider of Thryv®, the leading small business software platform, announced today members of its management team will host 1:1 meetings at the following upcoming investor conferences:
- ACCESSWIRE
New Survey Data from Thryv Finds 51% of Small Businesses Expect to Use AI by End of 2025
More than half of current AI users say it will save them up to $2K per month DALLAS, TX / ACCESSWIRE / May 22, 2024 / Small business adoption of AI will soon see a big rise. While only 39 percent of small businesses are currently using AI, that percentage ...
- CNW Group
Thryv Therapeutics to Present Preclinical Data of SGK1 Inhibition in Models of Drug-Induced QT Prolongation at the 2024 Heart Rhythm Society Meeting
Thryv Therapeutics Inc., a biotechnology company pioneering precision treatment to treat indications including Congenital Long QT Syndrome, atrial fibrillation, and heart failure, today announced a poster presentation of SGK1 inhibition in models of Drug-Induced QT prolongation at the 2024 Heart Rhythm Society meeting in Boston, MA. This presentation will take place on Friday, May 17th, from 10:30 a.m. to 12:30 p.m. ET. The meeting will commence with a presentation by Thryv co-founder and Princi
